Regeneron Pharmaceuticals, Inc.
REGN NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Jul 30, 2026
ET
EPS Est.
10.16
EPS Actual
14.29
Revenue Est.
$3.82B
Revenue Actual
$4.29B
Next Earnings Report
Date
Oct 28, 2026 · Wed
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
16.00
Revenue Est.
$4.54B
Company Overview
Regeneron Pharmaceuticals, Inc. (ticker REGN) is listed on NASDAQ with a market cap of about $85.92B. Its next earnings report (FY2026 Q3) is expected on Oct 28, 2026 (ET), Pre-market, with consensus EPS of 16.00. In the last 15 reported quarters, EPS beat consensus estimates 13 times.
Actual EPS TrendRecently15Term · Feb 3, 2023 → Jul 30, 2026
Feb 3, 2023Range: 8.22 ~ 14.29Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | 10.16 | Above forecast↑14.29 | $3.82B | $4.29B |
| Apr 29, 2026 | -- | 8.91 | 9.47 | $3.48B | $3.61B |
| Jan 30, 2026 | -- | 10.74 | 11.44 | $3.81B | $3.88B |
| Oct 28, 2025 | -- | 9.65 | Above forecast↑11.83 | $3.59B | $3.75B |
| Aug 1, 2025 | -- | 8.43 | Above forecast↑12.89 | $3.29B | $3.68B |
| Apr 29, 2025 | -- | 8.62 | 8.22 | $3.25B | $3.03B |
| Feb 4, 2025 | -- | 11.21 | 12.07 | $3.74B | $3.79B |
| Oct 31, 2024 | -- | 11.69 | 12.46 | $3.67B | $3.72B |
| Aug 1, 2024 | -- | 10.61 | 11.56 | $3.38B | $3.55B |
| May 2, 2024 | -- | 10.17 | 9.55 | $3.23B | $3.15B |
| Feb 2, 2024 | -- | 10.73 | 11.86 | $3.29B | $3.43B |
| Nov 2, 2023 | -- | 10.72 | 11.59 | $3.22B | $3.36B |
| Aug 3, 2023 | -- | 9.84 | 10.24 | $3.02B | $3.16B |
| May 4, 2023 | -- | 9.25 | 10.09 | $3B | $3.16B |
| Feb 3, 2023 | -- | 10.03 | Above forecast↑12.56 | $3.12B | $3.41B |
Original Filings (SEC)
10-Q2026-07-30 ↗
8-K2026-07-30 ↗
8-K2026-07-06 ↗
8-K2026-06-17 ↗
10-Q2026-04-29 ↗
8-K2026-04-29 ↗
8-K2026-04-08 ↗
10-K2026-02-04 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
